PE20110810A1 - Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 - Google Patents

Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38

Info

Publication number
PE20110810A1
PE20110810A1 PE2011000798A PE2011000798A PE20110810A1 PE 20110810 A1 PE20110810 A1 PE 20110810A1 PE 2011000798 A PE2011000798 A PE 2011000798A PE 2011000798 A PE2011000798 A PE 2011000798A PE 20110810 A1 PE20110810 A1 PE 20110810A1
Authority
PE
Peru
Prior art keywords
compound
formula
mitogen
protein kinase
inhibitors
Prior art date
Application number
PE2011000798A
Other languages
English (en)
Spanish (es)
Inventor
Kazuhiro Ito
Catherine Elisabeth Charron
Peter Strong
Stuart Thomas Onions
Jonathan Gareth Williams
John King-Underwood
William Garth Rapeport
Peter John Murray
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110810(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of PE20110810A1 publication Critical patent/PE20110810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PE2011000798A 2008-10-02 2009-10-02 Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 PE20110810A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0818033.3A GB0818033D0 (en) 2008-10-02 2008-10-02 Novel compound

Publications (1)

Publication Number Publication Date
PE20110810A1 true PE20110810A1 (es) 2011-11-08

Family

ID=40019929

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000798A PE20110810A1 (es) 2008-10-02 2009-10-02 Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38

Country Status (32)

Country Link
US (1) US8293771B2 (cg-RX-API-DMAC7.html)
EP (1) EP2350047B1 (cg-RX-API-DMAC7.html)
JP (1) JP5571088B2 (cg-RX-API-DMAC7.html)
KR (1) KR101660266B1 (cg-RX-API-DMAC7.html)
CN (1) CN102203078B (cg-RX-API-DMAC7.html)
AU (1) AU2009299554B8 (cg-RX-API-DMAC7.html)
CA (1) CA2738827C (cg-RX-API-DMAC7.html)
CL (1) CL2011000735A1 (cg-RX-API-DMAC7.html)
CO (1) CO6351785A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110230A (cg-RX-API-DMAC7.html)
CY (1) CY1114665T1 (cg-RX-API-DMAC7.html)
DK (1) DK2350047T3 (cg-RX-API-DMAC7.html)
EA (1) EA019590B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11010948A (cg-RX-API-DMAC7.html)
ES (1) ES2428917T3 (cg-RX-API-DMAC7.html)
GB (1) GB0818033D0 (cg-RX-API-DMAC7.html)
HN (1) HN2011000874A (cg-RX-API-DMAC7.html)
HR (1) HRP20130895T1 (cg-RX-API-DMAC7.html)
ME (1) ME01604B (cg-RX-API-DMAC7.html)
MX (1) MX2011003552A (cg-RX-API-DMAC7.html)
MY (1) MY150611A (cg-RX-API-DMAC7.html)
NI (1) NI201100062A (cg-RX-API-DMAC7.html)
NZ (1) NZ591426A (cg-RX-API-DMAC7.html)
PE (1) PE20110810A1 (cg-RX-API-DMAC7.html)
PL (1) PL2350047T3 (cg-RX-API-DMAC7.html)
PT (1) PT2350047E (cg-RX-API-DMAC7.html)
RS (1) RS52979B (cg-RX-API-DMAC7.html)
SI (1) SI2350047T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201300097B (cg-RX-API-DMAC7.html)
UA (2) UA105014C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010038085A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103181B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2709257C (en) 2007-12-19 2016-12-13 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
MX2011003553A (es) 2008-10-02 2011-05-25 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
JP2012511563A (ja) * 2008-12-11 2012-05-24 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
EP2236505A1 (de) * 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) * 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
ES2469367T3 (es) 2010-02-01 2014-06-18 Cancer Research Technology Limited 1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124930A1 (en) * 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
JP5973426B2 (ja) 2010-06-17 2016-08-23 レスピバート・リミテツド Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
CA2846222C (en) 2011-10-03 2020-07-07 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1- yl) ureas as p38 map kinase inhibitors
EP2788345B1 (en) * 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033447A2 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
US9783556B2 (en) 2012-08-29 2017-10-10 Respivert Limited Kinase inhibitors
US9732063B2 (en) 2012-11-16 2017-08-15 Respivert Limited Kinase inhibitors
EP2970190A1 (en) 2013-03-14 2016-01-20 Respivert Limited Kinase inhibitors
KR102283883B1 (ko) 2013-04-02 2021-07-29 옥슬러 액퀴지션즈 리미티드 키나제 저해제
US9771353B2 (en) 2013-04-02 2017-09-26 Topivert Pharma Limited Kinase inhibitors based upon N-alkyl pyrazoles
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
CA2938924C (en) 2014-02-14 2023-01-31 Respivert Limited Pyrazolyl-ureas as kinase inhibitors
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
CN109071505B (zh) 2016-04-06 2021-11-16 奥苏拉收购有限公司 激酶抑制剂
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
CA3142097A1 (en) 2018-05-30 2019-12-05 Washington University Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
KR102789258B1 (ko) * 2022-10-26 2025-04-01 (의료)길의료재단 신규화합물 및 이를 유효성분으로 포함하는 폐섬유화증 예방 또는 치료용 약학 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
JP4403482B2 (ja) 1997-12-22 2010-01-27 バイエル コーポレイション 置換複素環尿素合成のための中間体およびその製造方法
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
JP2001526222A (ja) 1997-12-22 2001-12-18 バイエル コーポレイション アリールおよびヘテロアリール置換複素環尿素を使用するｐ３８キナーゼ活性の阻害
KR100622138B1 (ko) 1997-12-22 2006-09-13 바이엘 코포레이션 아릴 및 헤테로아릴 치환 헤테로고리형 우레아를 사용한라프 키나제의 저해
WO1999047529A1 (en) 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
MXPA03006749A (es) 2001-02-15 2004-05-31 Boehringer Ingelheim Pharma Proceso para la sintesis de compuestos de urea sustituidos con heteroarilo, utiles como agentes antiinflamatorios.
EP1392661A1 (en) 2001-05-16 2004-03-03 Boehringer Ingelheim Pharmaceuticals Inc. Diarylurea derivatives useful as anti-inflammatory agents
AU2002316459A1 (en) 2001-07-11 2003-01-29 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
AU2003210969A1 (en) * 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
BR0309009A (pt) 2002-04-05 2005-03-22 Boehringer Ingelheim Pharma Método para o tratamento de hipersecreção de muco
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003268424A1 (en) 2002-09-05 2004-03-29 Scios Inc. Treatment of pain by inhibition of p38 map kinase
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
ES2357288T3 (es) 2003-02-28 2011-04-25 Bayer Healthcare Llc Derivados de 2-oxo-1,3,5-perhidrotriazapina útiles en el tratamiento de angiogénesis hiperproliferativa y trastornos inflamatorios.
MXPA05009459A (es) 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
GB0308511D0 (en) 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
WO2004101529A1 (ja) 2003-05-19 2004-11-25 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
BRPI0413757A (pt) 2003-08-22 2006-10-31 Boehringer Ingelheim Pharma métodos para o tratamento de copd e da hipertensão pulmonar
AU2004291147A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
JP2007535558A (ja) 2004-04-29 2007-12-06 ファーミックス コーポレイション キナーゼおよび／またはｈｍｇ−ｃｏａレダクターゼを阻害するための組成物および処置
CN101010315A (zh) 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
ATE460402T1 (de) 2004-05-12 2010-03-15 Bristol Myers Squibb Co Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1- rezeptors
PT1761520E (pt) 2004-06-23 2008-09-15 Lilly Co Eli Inibidores de quinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2589274A1 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2008524213A (ja) 2004-12-20 2008-07-10 アストラゼネカ・アクチエボラーグ 新規なピラゾール誘導体及びニコチン性アセチルコリン受容体のモジュレーターとしてのそれらの使用
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
CA2592116A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
DE102005015253A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Pyrazolderivate
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007038425A2 (en) 2005-09-27 2007-04-05 Regents Of The University Of Minnesota Anti-viral compouinds
CA2629468A1 (en) 2005-11-15 2007-05-24 Bayer Pharmaceuticals Corporation Pyrazolyl urea derivatives useful in the treatment of cancer
CA2631746A1 (en) 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer
TW200817409A (en) 2006-08-04 2008-04-16 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
JP5474065B2 (ja) * 2008-07-31 2014-04-16 ヒューレット−パッカード デベロップメント カンパニー エル．ピー． 光信号を増幅、変調及び検出するためのナノワイヤの光学的ブロック・デバイス
MX2011003553A (es) 2008-10-02 2011-05-25 Respivert Ltd Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
JP2012511563A (ja) * 2008-12-11 2012-05-24 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤

Also Published As

Publication number Publication date
EP2350047A2 (en) 2011-08-03
NZ591426A (en) 2012-12-21
UA105014C2 (uk) 2014-04-10
US20110269800A1 (en) 2011-11-03
ECSP11010948A (es) 2011-06-30
AU2009299554B2 (en) 2013-11-21
MX2011003552A (es) 2011-05-25
KR101660266B1 (ko) 2016-09-27
SI2350047T1 (sl) 2013-11-29
PT2350047E (pt) 2013-10-01
CA2738827C (en) 2017-02-28
CO6351785A2 (es) 2011-12-20
HK1157781A1 (en) 2012-07-06
JP2012504590A (ja) 2012-02-23
DK2350047T3 (da) 2013-09-30
CN102203078A (zh) 2011-09-28
MY150611A (en) 2014-01-30
RS52979B (sr) 2014-02-28
UA104731C2 (ru) 2014-03-11
PL2350047T3 (pl) 2013-12-31
CN102203078B (zh) 2014-06-25
BRPI0920840A2 (pt) 2020-10-20
KR20110065544A (ko) 2011-06-15
CL2011000735A1 (es) 2011-10-14
EA201170520A1 (ru) 2011-12-30
WO2010038085A3 (en) 2010-06-24
HN2011000874A (es) 2014-02-03
EA019590B1 (ru) 2014-04-30
ME01604B (me) 2014-09-20
SMT201300097B (it) 2013-11-08
JP5571088B2 (ja) 2014-08-13
NI201100062A (es) 2011-10-21
ES2428917T3 (es) 2013-11-12
US8293771B2 (en) 2012-10-23
CA2738827A1 (en) 2010-04-08
ZA201103181B (en) 2012-10-31
AU2009299554A1 (en) 2010-04-08
HRP20130895T1 (en) 2013-10-25
GB0818033D0 (en) 2008-11-05
EP2350047B1 (en) 2013-06-26
WO2010038085A2 (en) 2010-04-08
CR20110230A (es) 2011-11-10
CY1114665T1 (el) 2016-10-05
AU2009299554B8 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
PE20110810A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
NO20080897L (no) Salter av 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201200653A1 (ru) Гетариламинохинолины
CL2011002442A1 (es) Un compuesto n-(4-(4-(3-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)ureido)naftalen-1-iloxi)piridin-2-il)-2-metoxiacetamida o una sal, estereoisomeros y tautomeros del mismo; composicion farmaceutica; y su uso para tratar o prevenir una afeccion seleccionada de epoc, asma e inhibicion del crecimiento y metastasis de tumores, entre otras.
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
AR060648A1 (es) Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina
NO20080820L (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
EA201100093A1 (ru) Тиадиазолилоксифениламидины и применение их в качестве фунгицидов
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201490730A1 (ru) 1-пиразолил-3-(4-((2-анилинопиримидин-4-ил)окси)нафталин-1-ил)мочевины как ингибиторы p38 map-киназы
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
ATE472542T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
ATE455110T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
CL2016001023A1 (es) Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed